CN1233372C - 治疗心脑血管疾病含银杏叶提取物的口服复方药物制剂 - Google Patents
治疗心脑血管疾病含银杏叶提取物的口服复方药物制剂 Download PDFInfo
- Publication number
- CN1233372C CN1233372C CN 03132997 CN03132997A CN1233372C CN 1233372 C CN1233372 C CN 1233372C CN 03132997 CN03132997 CN 03132997 CN 03132997 A CN03132997 A CN 03132997A CN 1233372 C CN1233372 C CN 1233372C
- Authority
- CN
- China
- Prior art keywords
- dipyridamole
- folium ginkgo
- ginkgo extract
- biloba extract
- ginkgo biloba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 244000194101 Ginkgo biloba Species 0.000 title abstract 2
- 238000000605 extraction Methods 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 35
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960002768 dipyridamole Drugs 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 239000002775 capsule Substances 0.000 claims abstract description 14
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 14
- 239000007901 soft capsule Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 241000218628 Ginkgo Species 0.000 claims description 36
- 235000011201 Ginkgo Nutrition 0.000 claims description 36
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 36
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 8
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 abstract description 7
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract description 7
- 108010003541 Platelet Activating Factor Proteins 0.000 abstract description 7
- 230000008485 antagonism Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 4
- 229940068052 ginkgo biloba extract Drugs 0.000 abstract 6
- 235000020686 ginkgo biloba extract Nutrition 0.000 abstract 6
- 206010050661 Platelet aggregation inhibition Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 229960003511 macrogol Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 229940126532 prescription medicine Drugs 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03132997 CN1233372C (zh) | 2003-07-25 | 2003-07-25 | 治疗心脑血管疾病含银杏叶提取物的口服复方药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03132997 CN1233372C (zh) | 2003-07-25 | 2003-07-25 | 治疗心脑血管疾病含银杏叶提取物的口服复方药物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1569060A CN1569060A (zh) | 2005-01-26 |
CN1233372C true CN1233372C (zh) | 2005-12-28 |
Family
ID=34470002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03132997 Expired - Fee Related CN1233372C (zh) | 2003-07-25 | 2003-07-25 | 治疗心脑血管疾病含银杏叶提取物的口服复方药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1233372C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100336516C (zh) * | 2005-06-03 | 2007-09-12 | 贵州益佰科技研发有限责任公司 | 银杏叶提取物与双嘧达莫的复方药物及制备方法 |
CN1939357B (zh) * | 2005-09-27 | 2010-12-15 | 博安兄弟制药(中国)有限公司 | 一种银杏达莫注射液的制备方法 |
-
2003
- 2003-07-25 CN CN 03132997 patent/CN1233372C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1569060A (zh) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1085527C (zh) | 增效复方抗疟药本芴醇的制备方法 | |
CN1084616C (zh) | 扑热息痛和哌双咪酮的膜包衣片剂 | |
CN1253497A (zh) | 含扑热息痛的吞咽片剂 | |
EP2934488A1 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
Noman et al. | Preformulation and Characterization Studies of Clopidogrel Active Ingredient for Orodispersible Tablets Development | |
CN1233372C (zh) | 治疗心脑血管疾病含银杏叶提取物的口服复方药物制剂 | |
Gunda et al. | A statistical study on the formulation development of sustained release tablets for valsartan sodium | |
CN1660420A (zh) | 一种用于降低全血粘度、溶栓、降脂的复方中药组合物 | |
CN1087168C (zh) | 抗疟疾协同组合物 | |
CN104546793B (zh) | 一种降糖鸡腿蘑胶囊制剂及其制备方法 | |
RU2539375C1 (ru) | Фармацевтическая композиция в форме таблетки и способ ее получения | |
CN117180264A (zh) | 五味子乙素在制备镇痛药物中的应用 | |
CN1965878A (zh) | 含乙酰谷酰胺和红花有效成分的药物组合物及其制剂 | |
CN1069519C (zh) | 草乌甲素软胶囊及其生产方法 | |
CN1080855A (zh) | 维生素矿物质防癌复方 | |
CN1287808C (zh) | 银杏叶提取物组合物 | |
CN1742732A (zh) | 西力士滴丸及其制备方法 | |
CN1430964A (zh) | 一种含有桑叶总碱浸膏的制剂及其制备方法 | |
CN1238002C (zh) | 治疗胃肠疾病药物有效成份的提取方法及提取物的应用 | |
CN105367563A (zh) | 利伐沙班晶iv型物质及制备方法和其组合物与用途 | |
EP1121124A1 (en) | Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine | |
CN1454596A (zh) | 一种银杏叶提取物与双嘧达莫复方药物及其制备方法 | |
WO1993015729A1 (fr) | Agent d'attenuation des effets secondaires | |
CN1072492C (zh) | 贯众有效部位在制备抗疟药剂中的应用 | |
CN1795909A (zh) | 一种治疗跌打损伤的七厘制剂及其生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHAO YANYI Free format text: FORMER OWNER: LI BINGYANG; ZHANG XIAOYOU; JU WENYAN Effective date: 20080627 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080627 Address after: No. 245, Jianshe Road, Daqing hi tech Zone, Heilongjiang, 163319 Patentee after: Zhao Yanyi Address before: Room 302, unit 3, building 32, Longxin District, Daqing, Heilongjiang, China: zip code: 163001 Co-patentee before: Zhang Xiaoyou Patentee before: Li Ping Yang Co-patentee before: Ju Wenyan |
|
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG TIANYI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO YANYI Effective date: 20100928 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 163319 TO: 163316 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100928 Address after: 163316 Jianshe Road high tech Zone, Heilongjiang, No. 245, Patentee after: Heilongjiang Tianyi Pharmaceutical Co., Ltd. Address before: 163319 No. 245, Daqing hi tech Development Zone, Heilongjiang, Jianshe Road Patentee before: Zhao Yanyi |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051228 Termination date: 20160725 |
|
CF01 | Termination of patent right due to non-payment of annual fee |